<strong>Treatment for Lower Urinary Tract Dysfunction in Patients with Parkinson’s Disease</strong>

Abstract

CLC Number:

R964

WU Zhi-gang，SHEN Li-xia.Treatment for Lower Urinary Tract Dysfunction in Patients with Parkinson’s Disease[J]. Acta Neuropharmacologica, 2014, 4(4): 36-41.

[1] Jain S. Multi-organ autonomic dysfunction in Parkinson disease. Parkinsonism Relat Disord. 2011, 17(2):77-83.

[2] Badri AV, Purohit RS, Skenazy J, et al. A review of lower urinary tract symptoms in patients with Parkinson's disease. Curr Urol Rep. 2014, 15(9):435-443.

[3] Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008, 9(6):453-466.

[4] 胡钢. 帕金森病膀胱尿道功能障碍的研究[D]. 重庆,重庆医科大学,2007:21-22.

[5] 姜良真. 耻骨上经膀胱前列腺切除术与耻骨后前列腺切除术手术疗效比较及神经原性膀胱的尿动力学分析[D]. 天津,天津医科大学,2009:50-51.

[6] Aranda B, Cramer P. Effect of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn. 1993, 12(3): 203-209.

[7] Winge K, Werdelin LM, Nielsen KK, et al. Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol Urodyn. 2004, 23(7):689-696.

[8] Kuno S, Mizuta E, Yamasaki S, et al. Effects of pergolide on nocturia in Parkinson’s disease: three female cases selected from over 400 patients. Parkinsonism Relat Disord. 2004, 10(3):181-187.

[9] Fitzmaurice H, Fowler CJ, Rickards D, et al. Micturition disturbance in Parkinson’s disease. Br J Urol. 1985; 57(6):652-656.

[10] Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson’s disease. Trend Neurosci. 2000; 23(10 Suppl): S2–S7.

[11] 孙颖浩. ?1受体阻滞剂治疗良性前列腺增生研究进展[J]. 中华男科学杂志,2004,10(7):483-485.

[12] Gomes CM, Sammour ZM, Bessa Junior Jd, et al. Neurological status predicts response to alpha-blockers in men with voiding dysfunction and Parkinson's disease. Clinics (Sao Paulo). 2014, 69(12):817-822.

[13] Donnellan CA, Fook L, McDonald P, et al. Oxybutynin and cognitive dysfunction. BMJ 1997, 315(7119):1363–1364.

[14] 张辰珠,姚建. 曲司氯铵治疗膀胱过动症[J]. 世界临床药物, 2006, 27(6):359-363.

[15] 薛晓岩,于天民. 达非那新治疗特发性急迫性尿失禁30例[J]. 中国民康医学,2013,25(11):73-74.

[16] Dykstra DD, Sidi AA, Scott AB, et al. Effects of botulinum toxin A on detrusor sphincter dyssynergia in spinal cord injury patients. J Urol. 1988,139(5):919–922

[17] 陈俊男. A型肉毒毒素对神经和肌肉影响的效价研究[D].上海市, 第二军医大学,2008:1-2.

[18] Kapoor S, Bourdoumis A, Mambu L, et al. Effective management of lower urinary tract dysfunction in idiopathic Parkinson’s Disease. Int J Urol. 2013; 20(1):79–84.

[19] Giannantoni A, Conte A, Proietti S, et al. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J Urol. 2011, 186(3):960–964.

[20] Cone EB, Ellsworth P. Neurogenic detrusor overactivity: an update on management options. R I Med J. 2013, 96(4):38–40.

[21] Sakakibara R, Ito T, Uchiyama T, et al. Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment. Urol Int. 2008, 81(3):335–339.

[22] Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s disease. Mov Disord.1995, 10(3):337–340.

[23] Igawa Y, Michel MC. Pharmacological profile of β3-adrenoceptor agonists in clincal development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol. 2013, 386(3):177–183.

[24] 何鹏彬,查培金,徐东萍. 磷酸二酯酶-5抑制剂治疗良性前列腺增生所致下尿路症状的研究进展[J].中华男科学杂志,2014,20(7):651-654.

[25] Proietti S, Giannantoni A, Sahai A, et al. Overactive bladder and sexual function: a nightmare couple. BJU Int. 2012, 110(7):921–924.

[26] Ashkan K, Samuel M, Reddy P, et al. The impact of deep brain stimulation on the nonmotor symptoms of Parkinson's disease. J Neural Transm. 2013, 120(4):639-642.

[27] Dostrovsky JO, Lozano AM. Mechanisms of deep brain stimulation. Mov Disord. 2002, 17 (Supple 3): S63–S68.

[28] Shimizu N1, Matsumoto S, Mori Y, et al. Effects of deep brain stimulation on urodynamic findings in patients with Parkinson's disease. Hinyokika Kiyo. 2007, 53(9):609-612.

[29] Phé V, Caremel R, Bart S, et al. Lower urinary tract dysfunctions in parkinsonian syndromes: a review by the Neuro-Urology Comittee of the French Association of Urology. Prog Urol.2013, 23(5):296–308.

[30] Ohannessian A, Kaboré FA, Agostini A, et al. Transcutaneous tibial nerve stimulation in the overactive bladder syndrome in patients with Parkinson’s syndromes. Prog Urol. 2013, 23(11):936–939.

[31] Staskin DS, Vardi Y, Siroky MB. Post-prostatectomy continence in the parkinsonian patient: the significance of poor voluntary sphincter control. J Urol. 1988, 140(1):117–118.

[32] Roth B, Studer UE, Fowler CJ, et al. Benign prostatic obstruction and parkinson’s disease-should transurethral resection of the prostate be avoided? J Urol. 2009, 181(5):2209–2213.

[33] Lehana Yeo, Rajindra Singh, Mohan Gundeti, et al. Urinary tract dysfunction in Parkinson’s disease: a review [J]. Int Urol Nephrol.2012, 44(2):415-424.

[34] 黄嘉,张庆霞,梁文蔚. 艾灸治疗帕金森病排尿障碍31例[J]. 中国中医药现代远程教育,2012,10(7):46-47.

[35] 陈义良,张小莉,周国林. 针灸推拿结合药物治疗脑外伤后综合征42例临床观察[J]. 江苏中医药,2010,42(4):53-54.

[36] 陈义良,冯为菊,张小莉. 针药结合治疗帕金森病合并膀胱过度活动症[J]. 中国针灸,2012,32(3):215-218.

Treatment for Lower Urinary Tract Dysfunction in Patients with Parkinson’s Disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

[1]	XIE bin, HUANG Zhi-yuan, LIN Duo-duo, YANG Fu-long, XIE Yi-bin.Effect of Acupuncture Combined with Medicine on Depressive Symptoms of Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 5-8.
[2]	SUN Li-cong, ZHANG Dan-shen.Research Progress on Potential Treatment of Alzheimer’s Disease with Alkaloids[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 33-37.
[3]	WANG Si-yi, LI Xian-xiang, LIU Yi-zhou, DU Shuang, GE Chao, LIU Si-si.Current Situation and Prospect of Alzeimer’s Disease Treatment[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 38-42.
[4]	ZHAO Yu-wei, ZHEN Yan-jie, DAI Yue-ying, SHEN Li-xia.Study on the Neuroprotective Mechanism of Quercetin in Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 55-64.
[5]	HAI Ji-tao, LUO Huan-min.Progress on the Relationship between Pathogenic Microorganisms and Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(4): 58-64.
[6]	LEI Luo-chun, AI Ying, YANG Jun-ying, ZHENG Wei.Effect of Routine and Optimized Treatment in ICU on Cerebral Resuscitation in Patients with Post-Cardiac Arrest Syndrome#br#[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(4): 1-4.
[7]	ZHANG Hao-ting, SONG Gui-qin, CUI Ruo-tong, HAO Min, WANG Wen-dong.Mining Target Genes of Alzheimer’s Disease Associated with Biological Clock by Bioinformatics Analysis[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 1-7.
[8]	YANG Xu-hua, DU Shuang, SHEN Li-xia, HAO Jun-rong.Research Progress in Drug Treatment of Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 47-53.
[9]	LIU Xuan, TENG Jin-liang.The Research of Dexmedetomidine on Postoperative Cognitive Dysfunction[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(2): 39-45.
[10]	ZHANG Li-huan, CHU Bao, ZHANG Xiao-yan, SUN Ying-ru, GONG Chun-dong, WANG He-bo.Research Progress of Magnesium in Pathogenesis and Treatment of Migraine[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(1): 29-33.
[11]	ZHEN Yan-jie, GUO Tong-lin, ZHAO Yu-wei, SHEN Li-xia.Study Progress on Phytoestrogen-Mediated Mitochondrial Pathway’s Neuroprotective Effects in Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(1): 40-46.
[12]	HE Pan, LIU Yue-tao, DU Guan-hua, QIN Xue-mei.Research Advances in Sarcopenia[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(1): 47-53.
[13]	YANG-Lin，AI-Jing.Research Progress of Brain-Derived Estrogen in Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2019, 9(5): 50-64.
[14]	ZHANG Shuai，AI Jing.Glutamate Dysfunction and Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2018, 8(6): 9-20.
[15]	王奇.Bushen-Yizhi Formula Inhibits the NLRP3/NFκB Mediated Neuroinflammation and Improves the Motor Dysfunction in a Mouse Model of Parkinson's Disease[J]. Acta Neuropharmacologica, 2018, 8(5): 71-72.